The European Directorate for the Quality of Medicines and Healthcare rates the corrective actions taken by the company on certain quality issues as appropriate. The European body had inspected the company’s Bavla site in February 2020.Dishman Carbogen Amcis expects turnaround in FY22, working on resolution of regulatory issues at Bavla site
The European Directorate for the Quality of Medicines and Healthcare rates the corrective actions taken by the company on certain quality issues as appropriate. The European body had inspected the company’s Bavla site in February 2020.
Subscribe to:
Post Comments (Atom)
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
No comments:
Post a Comment